Analysts expect that Myovant Sciences Ltd (NYSE:MYOV) will post earnings per share of ($1.02) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Myovant Sciences’ earnings, with estimates ranging from ($1.05) to ($0.97). Myovant Sciences posted earnings of ($0.81) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 25.9%. The company is expected to announce its next earnings report on Thursday, June 6th.
According to Zacks, analysts expect that Myovant Sciences will report full year earnings of ($4.02) per share for the current fiscal year, with EPS estimates ranging from ($4.07) to ($4.00). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.84) per share, with EPS estimates ranging from ($4.21) to ($3.50). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Myovant Sciences.
Myovant Sciences (NYSE:MYOV) last posted its earnings results on Thursday, February 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.06).
Shares of Myovant Sciences stock traded up $1.91 during trading on Friday, hitting $21.10. 1,631 shares of the stock were exchanged, compared to its average volume of 63,159. The stock has a market cap of $1.31 billion, a P/E ratio of -8.72 and a beta of 0.68. Myovant Sciences has a 12-month low of $13.13 and a 12-month high of $27.45. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 2.08.
In other news, Director Mark Altmeyer purchased 3,500 shares of the business’s stock in a transaction dated Saturday, November 17th. The shares were purchased at an average cost of $13.38 per share, with a total value of $46,830.00. Following the completion of the purchase, the director now owns 3,500 shares of the company’s stock, valued at approximately $46,830. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 3.10% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Opera Trading Capital purchased a new stake in Myovant Sciences during the 3rd quarter valued at $117,000. Atria Investments LLC acquired a new position in shares of Myovant Sciences during the third quarter worth $201,000. First Manhattan Co. acquired a new position in shares of Myovant Sciences during the fourth quarter worth $292,000. Renaissance Technologies LLC acquired a new position in shares of Myovant Sciences during the second quarter worth $297,000. Finally, BlackRock Inc. grew its stake in shares of Myovant Sciences by 5.2% during the fourth quarter. BlackRock Inc. now owns 27,912 shares of the company’s stock worth $458,000 after purchasing an additional 1,386 shares in the last quarter. Institutional investors and hedge funds own 25.86% of the company’s stock.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Featured Article: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.